Kidney cancer working group report

Seiji Naito, Yoshihiko Tomita, Sun Young Rha, Hirotsugu Uemura, Mototsugu Oya, He Zhi Song, Li Han Zhong, Mohamed Ibrahim Bin A. Wahid

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3% per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. Highdose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-α) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network, etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.

Original languageEnglish
Article numberhyq127
Pages (from-to)i51-i56
JournalJapanese Journal of Clinical Oncology
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Interleukin-2
Neoplasms
Incidence
Guidelines
Cystic Kidney Diseases
Phase III Clinical Trials
Disease Susceptibility
Therapeutics
Developed Countries
Interferon-alpha
Pharmaceutical Preparations
Immunotherapy
Consensus
Japan
Obesity
Smoking
History
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Naito, S., Tomita, Y., Rha, S. Y., Uemura, H., Oya, M., Song, H. Z., ... Wahid, M. I. B. A. (2010). Kidney cancer working group report. Japanese Journal of Clinical Oncology, 40(SUPPL. 1), i51-i56. [hyq127]. https://doi.org/10.1093/jjco/hyq127
Naito, Seiji ; Tomita, Yoshihiko ; Rha, Sun Young ; Uemura, Hirotsugu ; Oya, Mototsugu ; Song, He Zhi ; Zhong, Li Han ; Wahid, Mohamed Ibrahim Bin A. / Kidney cancer working group report. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. SUPPL. 1. pp. i51-i56.
@article{f0fe16b7abbb425ba2d02429da75f8fb,
title = "Kidney cancer working group report",
abstract = "Kidney cancer accounts for approximately 2{\%} of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3{\%} per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. Highdose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-α) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network, etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.",
author = "Seiji Naito and Yoshihiko Tomita and Rha, {Sun Young} and Hirotsugu Uemura and Mototsugu Oya and Song, {He Zhi} and Zhong, {Li Han} and Wahid, {Mohamed Ibrahim Bin A.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1093/jjco/hyq127",
language = "English",
volume = "40",
pages = "i51--i56",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

Naito, S, Tomita, Y, Rha, SY, Uemura, H, Oya, M, Song, HZ, Zhong, LH & Wahid, MIBA 2010, 'Kidney cancer working group report', Japanese Journal of Clinical Oncology, vol. 40, no. SUPPL. 1, hyq127, pp. i51-i56. https://doi.org/10.1093/jjco/hyq127

Kidney cancer working group report. / Naito, Seiji; Tomita, Yoshihiko; Rha, Sun Young; Uemura, Hirotsugu; Oya, Mototsugu; Song, He Zhi; Zhong, Li Han; Wahid, Mohamed Ibrahim Bin A.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. SUPPL. 1, hyq127, 01.09.2010, p. i51-i56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Kidney cancer working group report

AU - Naito, Seiji

AU - Tomita, Yoshihiko

AU - Rha, Sun Young

AU - Uemura, Hirotsugu

AU - Oya, Mototsugu

AU - Song, He Zhi

AU - Zhong, Li Han

AU - Wahid, Mohamed Ibrahim Bin A.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3% per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. Highdose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-α) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network, etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.

AB - Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3% per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. Highdose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-α) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network, etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.

UR - http://www.scopus.com/inward/record.url?scp=77957272015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957272015&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq127

DO - 10.1093/jjco/hyq127

M3 - Article

C2 - 20870920

AN - SCOPUS:77957272015

VL - 40

SP - i51-i56

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - SUPPL. 1

M1 - hyq127

ER -

Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ et al. Kidney cancer working group report. Japanese Journal of Clinical Oncology. 2010 Sep 1;40(SUPPL. 1):i51-i56. hyq127. https://doi.org/10.1093/jjco/hyq127